Market capitalization | $3.10m |
Enterprise Value | $70.75m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.35 |
P/S ratio (TTM) P/S ratio | 0.06 |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $52.47m |
EBIT (operating result TTM) EBIT | $-44.41m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Centogene NV:
1 Analyst has issued a forecast Centogene NV:
Dec '23 |
+/-
%
|
||
Revenue | 52 52 |
-
|
|
Gross Profit | 19 19 |
-
|
|
EBITDA | -36 -36 |
-
|
EBIT (Operating Income) EBIT | -44 -44 |
-
|
Net Profit | -38 -38 |
-
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Centogene NV is a commercial-stage company. It focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. It operates through the following two segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment provides services to pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery and patient monitoring. The Diagnostics segment provides targeted genetic sequencing and diagnostics services. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.
Head office | Netherlands |
CEO | Kim Stratton |
Employees | 493 |
Founded | 2018 |
Website | www.centogene.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.